Alembic Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,603 Cr +36.3% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
AP

Alembic Pharmaceuticals Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Alembic Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,848Cr
+4.4% YoY
−1.5% QoQ
Net profit
₹202Cr
+28.7% YoY
+53% QoQ
Margin
12%
−3 pp YoY
−4 pp QoQ

Alembic Pharmaceuticals Ltd Q4 FY26 key numbers

Revenue
U.S. business expected to grow 10-15% in INR terms (approximately 7-8% in constant currency).

As stated in Alembic Pharmaceuticals Ltd's Q4 FY26 earnings call transcript · published 24 May 2026. Reported figures, not investment advice.

Price₹822
Market cap₹16.1K Cr
P/E21.6

The short version

Alembic Pharmaceuticals targets low double-digit consolidated revenue growth in FY '27, driven by internal performance improvements amid stable external market conditions. - U.S. Alembic expects low double-digit consolidated top-line growth in FY '27 driven by international generics, API, and India businesses.

From Alembic Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • Alembic Pharmaceuticals targets low double-digit consolidated revenue growth in FY '27, driven by internal performance improvements amid stable external market conditions.
  • U.S. business expected to grow 10-15% in INR terms (approximately 7-8% in constant currency).
  • Rest of World (ex-U.S.) markets projected to grow 15%+ driven by new product launches and expanding footprints.
  • API business anticipated to grow around 10%, supported by volume increases.
  • India business aims to improve growth momentum, targeting growth closer to the overall market.
  • New product launches, especially Day 1 and First-to-File opportunities, along with contract manufacturing, will support volume growth.

2 more points from Alembic Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Alembic Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Alembic Pharmaceuticals is broadly done with all major capex, including peptide-related investments, which were part of ongoing API facility upgrades rather than dedicated peptide capex.
  • The branded business, including U.S. specialty branded operations like Pivya, does not require significant capex; investments are primarily in in-licensing products.
  • For FY '27, capital expenditure is expected in the range of INR 300-350 crores, focused on capacity expansion, debottlenecking, and replacement capex.
  • There will be continued, though measured, R&D investments (~INR 750-800 crores) to support complex products and expansion of the branded business.

2 more points from Alembic Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Alembic Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The following related points can be inferred: - Alembic expects product launches in the U.S. and ex-U.S. markets to be phased through FY '27, indicating an active pipeline for launches. - The company mentioned having a portfolio of 5-6 peptide filings, with two already filed and others ongoing, suggesting pending developmental projects. - Contract manufacturing deals for F2 and F3 facilities are already in progress, contributing to revenue in FY '27, implying active orders or partnerships.

2 more points from Alembic Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

What the Q4 FY26 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned

Alembic Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Alembic Pharmaceuticals Ltd Q4 FY26 results — key figures

Alembic Pharmaceuticals Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue1,8481,770+4.4%1,876-1.5%
Operating profit (EBITDA)228271-15.9%292-21.9%
Operating margin12%15%-3 pp16%-4 pp
Profit before tax119192-38%162-26.5%
Net profit (PAT)202157+28.7%132+53%
EPS (₹)10.317.98+29.2%6.76+52.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.6K Cr, net profit ₹334 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Alembic Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Alembic Pharmaceuticals Ltd Q4 FY26 results?

Alembic Pharmaceuticals targets low double-digit consolidated revenue growth in FY '27, driven by internal performance improvements amid stable external market conditions. - U.S. Alembic expects low double-digit consolidated top-line growth in FY '27 driven by international generics, API, and India businesses.

What is Alembic Pharmaceuticals Ltd share price analysis?

Alembic Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 21.6 with a market cap of ₹16,083 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alembic Pharmaceuticals Ltd planning capital expenditure?

Alembic Pharmaceuticals is broadly done with all major capex, including peptide-related investments, which were part of ongoing API facility upgrades rather than dedicated peptide capex. - The branded business, including U.S.

Keep Alembic Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.